However, as Smad2 also plays an essential role in the glucose-stimulated release of insulin in β cells 16, targeting Smad3 but not upstream TGFBR1 in islets (β cells) may be more favorable for cell replacement treatment of diabetes. The gene discussed is INS; the disease is diabetes mellitus.